BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9143413)

  • 1. Discordance in p53 mutations when comparing ascites and solid tumors from patients with serous ovarian cancer.
    Provencher DM; Lounis H; Fink D; Drouin P; Mes-Masson AM
    Tumour Biol; 1997; 18(3):167-74. PubMed ID: 9143413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
    Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
    Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
    Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mutations of p53 gene exons 5 to 8 in human ovarian cancer and its clinical significance].
    You Z; Guo Y; Wen H
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):660-3. PubMed ID: 9387525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.
    Naito M; Satake M; Sakai E; Hirano Y; Tsuchida N; Kanzaki H; Ito Y; Mori T
    Jpn J Cancer Res; 1992 Oct; 83(10):1030-6. PubMed ID: 1333465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of p53 mutations in bilateral breast carcinoma.
    Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
    Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in ovarian tumors, detected by temperature-gradient gel electrophoresis, direct sequencing and immunohistochemistry.
    Kappes S; Milde-Langosch K; Kressin P; Passlack B; Dockhorn-Dworniczak B; Röhlke P; Löning T
    Int J Cancer; 1995 Feb; 64(1):52-9. PubMed ID: 7665249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene and cell cycling in uveal melanoma.
    Kishore K; Ghazvini S; Char DH; Kroll S; Selle J
    Am J Ophthalmol; 1996 May; 121(5):561-7. PubMed ID: 8610800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
    Niwa K; Itoh M; Murase T; Morishita S; Itoh N; Mori H; Tamaya T
    Br J Cancer; 1994 Dec; 70(6):1191-7. PubMed ID: 7981076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?
    Magnusson KP; Satalino R; Qian W; Klein G; Wiman KG
    Oncogene; 1998 Nov; 17(18):2333-7. PubMed ID: 9811464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
    Bar JK; Harłozińska A; Popiela A; Noga L
    Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis.
    Kawasaki H; Ogura T; Yokose T; Nagai K; Nishiwaki Y; Esumi H
    Hum Pathol; 2001 Oct; 32(10):1043-9. PubMed ID: 11679937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 gene mutations and protein accumulation in human ovarian cancer.
    Kupryjańczyk J; Thor AD; Beauchamp R; Merritt V; Edgerton SM; Bell DA; Yandell DW
    Proc Natl Acad Sci U S A; 1993 Jun; 90(11):4961-5. PubMed ID: 8506342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 gene analysis of ovarian borderline tumors and stage I carcinomas.
    Kupryjanczyk J; Bell DA; Dimeo D; Beauchamp R; Thor AD; Yandell DW
    Hum Pathol; 1995 Apr; 26(4):387-92. PubMed ID: 7705816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.